Alembic Pharmaceuticals is currently trading at Rs. 631.20, up by 11.40 points or 1.84% from its previous closing of Rs. 619.80 on the BSE.
The scrip opened at Rs. 629.00 and has touched a high and low of Rs. 635.00 and Rs. 610.00 respectively. So far 9206 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 709.30 on 23-Mar-2017 and a 52 week low of Rs. 515.55 on 18-Apr-2016.
Last one week high and low of the scrip stood at Rs. 637.00 and Rs. 610.00 respectively. The current market cap of the company is Rs. 11565.45 crore.
The promoters holding in the company stood at 72.68%, while Institutions and Non-Institutions held 13.63% and 13.70% respectively.
Alembic Pharmaceuticals has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Fluoxetine Hydrochloride Tablets, 10 mg and 20mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Prozac Tablets, 10 mg and 20mg, of Eli Lilly and Company.
Fluoxetine Hydrochloride Tablets are indicated for the treatment of Major Depressive Disorder (MDD) and Obsessive Compulsive Disorder (OCD) in adult and pediatric patients. Fluoxetine Tablets are also indicated for treatment of binge eating and vomiting behaviour in moderate to severe Bulimia Nervosa and acute treatment of Panic Disorder, in adult patients.
Fluoxetine Hydrochloride Tablets have an estimated market size of $120 million for twelve months ending December 2015. Alembic now has a total of 53 ANDA approvals (47 final approvals and 6 tentative approvals) from the USFDA.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.
